Premium
Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia
Author(s) -
Lu PoHsien,
Tsai TzuCheng,
Chang John WenCheng,
Deng ShinTarng,
Cheng ChiYuan
Publication year - 2021
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.13298
Subject(s) - medicine , antibiotics , hazard ratio , proportional hazards model , lung cancer , confidence interval , retrospective cohort study , cohort , cohort study , microbiology and biotechnology , biology
Abstract What is known and objective Gut microbiota plays an important role in shaping immune responses. Several studies have reported that antibiotics may alter gut microbiota diversity and compromise the therapeutic response to immune checkpoint inhibitors (ICIs). Nevertheless, the impact of a specific class of antibiotics on ICIs therapy is still not known. The aim of this study was to analyse the influence of antibiotics on the clinical outcomes of non‐small cell lung cancer (NSCLC) patients treated with ICIs and to compare the effects of fluoroquinolones vs. other broad‐spectrum antibiotics. Methods This retrospective cohort study ( n = 340) analysed data from Chang Gung Research Database, which comprises work from seven medical institutions in Taiwan. Patients with NSCLC who received ICIs between January 2016 and March 2019 were evaluated. The data of patients who received antibiotics (ie fluoroquinolone) within 30 days prior to ICIs therapy were analysed. Overall survival (OS) was the goal of our study and was calculated from the time the ICIs therapy start. Survival analysis was estimated using the Kaplan‐Meier and Cox statistics. Results A total of 340 patients were identified for analysis. Of the 340 patients, only over one third (38%) of patients received antibiotics 30 days prior to ICI therapy. These patients exhibited a shorter OS compared with those not receiving antibiotics (median OS, 266 days vs. 455 days; hazard ratio (HR), 2.9; 95% confidence interval (CI), 1.1–8.1, p = 0.003). In this study, 127 out of 128 patients who were exposed to antibiotics had received at least one broad‐spectrum antibiotic. We observed patients who had received fluoroquinolone had a shorter OS compared with those receiving other broad‐spectrum antibiotics (median OS, 121 days vs. 370 days; HR, 1.582; 95% CI 1.007–2.841; p = 0.047). What is new and conclusion Antibiotic treatment, especially fluoroquinolone, prior to ICIs therapy was associated with poorer clinical efficacy in NSCLC patients. Antibiotics should not be withheld when there is a clear need for them despite the possibility of interfering with the microbiome, which may, in turn, adversely affect the ICI’s effectiveness. However, one should consider avoiding the use of fluoroquinolones antibiotics.